S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Options trading has suddenly become more reliable. (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The "Smart Money" Is Ready for May 1st Are You? (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Options trading has suddenly become more reliable. (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The "Smart Money" Is Ready for May 1st Are You? (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Options trading has suddenly become more reliable. (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The "Smart Money" Is Ready for May 1st Are You? (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Options trading has suddenly become more reliable. (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The "Smart Money" Is Ready for May 1st Are You? (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:VVOS

Vivos Therapeutics (VVOS) Stock Price, News & Analysis

→ Start loving Mondays like this (From DTI) (Ad)
Free VVOS Stock Alerts
$2.66
0.00 (0.00%)
(As of 04/18/2024 ET)
Compare
Today's Range
$2.60
▼
$2.79
50-Day Range
$2.64
▼
$5.81
52-Week Range
$2.40
▼
$48.79
Volume
63,256 shs
Average Volume
196,203 shs
Market Capitalization
$7.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
VVOS stock logo

About Vivos Therapeutics Stock (NASDAQ:VVOS)

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.

VVOS Stock Price History

VVOS Stock News Headlines

April 15, 2024 | americanbankingnews.com
TELA Bio (NASDAQ:TELA) vs. Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head Analysis
April 12, 2024 | americanbankingnews.com
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Drop in Short Interest
April 18, 2024 | Crypto 101 Media (Ad)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
April 11, 2024 | proactiveinvestors.com
Vivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approval
April 9, 2024 | finance.yahoo.com
Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices
April 9, 2024 | markets.businessinsider.com
Vivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral Devices
April 9, 2024 | msn.com
What's Going On With Vivos Therapeutics Stock?
April 9, 2024 | msn.com
Medicare to reimburse for Vivos CARE sleep apnea devices
April 18, 2024 | Crypto 101 Media (Ad)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
April 9, 2024 | proactiveinvestors.com
Vivos Therapeutics CARE oral medical devices approved for Medicare reimbursement
April 9, 2024 | investorplace.com
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?
April 9, 2024 | msn.com
Vivos Therapeutics files to sell 1.73M shares of common stock for holders
April 9, 2024 | finance.yahoo.com
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
April 9, 2024 | globenewswire.com
Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
April 1, 2024 | proactiveinvestors.com
Vivos Therapeutics highlights path to cash flow positivity after FDA clearance
March 31, 2024 | finance.yahoo.com
Vivos Therapeutics Full Year 2023 Earnings: Misses Expectations
March 30, 2024 | seekingalpha.com
Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript
March 29, 2024 | marketwatch.com
Vivos Therapeutics Shares Fall After Wider-Than-Expected 4Q Loss
March 28, 2024 | globenewswire.com
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
March 28, 2024 | globenewswire.com
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
February 22, 2024 | benzinga.com
Vivos Therapeutics Stock (NASDAQ:VVOS), Short Interest Report
February 22, 2024 | benzinga.com
Vivos Therapeutics Stock (NASDAQ:VVOS) Insider Trades
February 18, 2024 | investing.com
Vivos Therapeutics secures $4 million through warrant exercise
February 15, 2024 | finance.yahoo.com
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
February 15, 2024 | proactiveinvestors.com
Vivos Therapeutics sees gross proceeds of $4M from exercise of warrant
February 12, 2024 | finance.yahoo.com
Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions
February 6, 2024 | finanznachrichten.de
Vivos Therapeutics, Inc: Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
See More Headlines
Receive VVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
4/18/2024
Next Earnings (Estimated)
6/13/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:VVOS
CUSIP
N/A
CIK
1716166
Web
www.vivoslife.com
Phone
866-908-4867
Fax
N/A
Employees
154
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($11.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-13,580,000.00
Net Margins
-98.42%
Pretax Margin
-98.42%
Return on Equity
-665.17%
Return on Assets
-122.48%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.34
Quick Ratio
0.34

Sales & Book Value

Annual Sales
$13.80 million
Price / Sales
0.53
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.22 per share
Price / Book
12.09

Miscellaneous

Outstanding Shares
2,730,000
Free Float
2,469,000
Market Cap
$7.26 million
Optionable
Optionable
Beta
7.94
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VVOS Stock Analysis - Frequently Asked Questions

How have VVOS shares performed in 2024?

Vivos Therapeutics' stock was trading at $12.44 at the beginning of 2024. Since then, VVOS shares have decreased by 78.6% and is now trading at $2.66.
View the best growth stocks for 2024 here.

Are investors shorting Vivos Therapeutics?

Vivos Therapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 18,700 shares, a decrease of 28.6% from the March 15th total of 26,200 shares. Based on an average daily trading volume, of 208,400 shares, the short-interest ratio is currently 0.1 days. Approximately 0.8% of the shares of the stock are short sold.
View Vivos Therapeutics' Short Interest.

When is Vivos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 13th 2024.
View our VVOS earnings forecast.

How were Vivos Therapeutics' earnings last quarter?

Vivos Therapeutics, Inc. (NASDAQ:VVOS) issued its quarterly earnings results on Thursday, March, 28th. The company reported ($3.05) EPS for the quarter. The business earned $3.25 million during the quarter. Vivos Therapeutics had a negative net margin of 98.42% and a negative trailing twelve-month return on equity of 665.17%.

When did Vivos Therapeutics' stock split?

Vivos Therapeutics shares reverse split on the morning of Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Vivos Therapeutics IPO?

Vivos Therapeutics (VVOS) raised $20 million in an IPO on Friday, December 11th 2020. The company issued 3,300,000 shares at $5.00-$7.00 per share. Roth Capital Partners served as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

How do I buy shares of Vivos Therapeutics?

Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VVOS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
SHOCKING Crypto Leak…
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
How Biden has already won 2024
Porter & Company